Dr. Kambiz Soleymani, MD

Dr. Soleymani practices at Passages in Barboursville, West Virginia.

Dr. Soleymani's NPI, 1740394576, was assigned on August 18, 2006. Dr. Soleymani holds West Virginia license 21654.

Dr. Soleymani's primary practice is Passages, at 3012 Champion Dr, Barboursville, WV 25504 in Cabell County. The practice phone is (304) 972-6767.

Dr. Soleymani's primary practice is Passages in Barboursville, West Virginia. The medical group on file is Passages LLC. Dmand AI also links Dr. Soleymani to 2 more group practices and clinics, 1 physician office and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Soleymani practices, 3 sites in all. Vendor and product names are available with a free account.

Psychiatry is Dr. Soleymani's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Soleymani is licensed in West Virginia.

CMS data shows 291 Medicare services from Dr. Soleymani across 2 procedure codes in 2024, all of them office visits, for 55 Medicare patients. Medicare paid $13,943 for them. Every service was in an office.

CMS counts 55 Medicare patients who saw Dr. Soleymani in 2024. The largest group is under 65, with 27 patients. 75% of them have anxiety, and 75% have high blood pressure. 53% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Soleymani's median patient age at 47, with 43% women.

In 2024, Dr. Soleymani wrote 4,108 Medicare Part D claims for 184 patients. 96% of them were for generic drugs. CMS names the drug for 3,993 of them, across 43 drugs with 11 or more claims each, at $99,847 in total drug cost. In 2023, CMS named 6,011 claims across 57 drugs.

Dr. Soleymani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Soleymani as offering telehealth.

CMS Open Payments shows 88 general payments to Dr. Soleymani from 16 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 82% of the total. Otsuka America Pharmaceutical, Inc. paid the most, $883.